Lipanthyl

Fenofibrate, the active ingredient in Lipanthyl, is a fibrate presented as a tablet for oral use. It is prescribed to lower elevated blood lipids, particularly in patients with high cholesterol or triglyceride levels, and works by modifying lipid metabolism to reduce cardiovascular risk associated with dyslipidemia.

GNH USA supplies Lipanthyl as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, ensuring quality manufacturing standards and reliable global distribution for this essential lipid‑modifying agent.

Lipanthyl (fenofibrate) is used to treat disorders of lipid metabolism.

Hypercholesterolemia: reduces LDL‑cholesterol and total cholesterol levels. Hypertriglyceridemia: lowers elevated triglyceride concentrations. Mixed dyslipidemia: improves overall lipid profile by decreasing triglycerides and LDL while modestly raising HDL.

Fenofibrate may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Gastrointestinal discomfort: nausea, dyspepsia, or abdominal pain. - Headache: mild to moderate intensity. - Muscle pain: occasional myalgia without weakness. - Elevated liver enzymes: mild transaminase increases. - Elevated serum creatinine: transient rise in renal markers. - Skin rash: mild pruritic eruptions.

Serious or Rare Side Effects: - Rhabdomyolysis: severe muscle breakdown with risk of renal failure. - Hepatotoxicity: significant liver injury or hepatitis. - Severe allergic reaction: anaphylaxis or angioedema. - Pancreatitis: acute inflammation of the pancreas. - Myopathy with renal impairment: exacerbated muscle toxicity in patients with reduced kidney function. - Gallstone formation: rare occurrence of biliary sludge or stones.

When prescribing fenofibrate, clinicians should consider several safety precautions.

Renal function: assess baseline kidney function and monitor periodically. Liver disease: evaluate hepatic enzymes before initiation and during therapy. Gallbladder disease: use with caution in patients with a history of gallstones. Pregnancy: avoid unless potential benefit justifies the risk. Drug interactions: review concomitant medications for possible interactions. Store at ambient temperature: keep in the original packaging, protect from moisture and light.

Fenofibrate can interact with other medicines, requiring careful management.

Major Interactions (Avoid): - Gemfibrozil: markedly increases risk of myopathy and rhabdomyolysis. - Cyclosporine: elevates fenofibrate plasma concentrations. - Warfarin: may enhance anticoagulant effect and increase INR.

Moderate Interactions (Monitor Closely): - Statins: combined use can raise the likelihood of muscle toxicity. - Antidiabetic agents: may affect glycemic control, requiring dose adjustments. - Thiazide diuretics: can increase serum uric acid levels, potentially precipitating gout.